Table 3.

Treatment-related TEAEs in ≥10% of patients (NCI-CTCAE v3.0)

Q3W
0.25 mg/kg0.5 mg/kg1 mg/kg2 mg/kg4 mg/kgTotal
Adverse event a N = 7N = 6N = 6N = 6N = 6N = 31
Headache7 (27%)
 Grade 1001023 (10%)
 Grade 2102104 (13%)
Fatigue6 (19%)
 Grade 1002114 (13%)
 Grade 2000112 (7%)
Nausea6 (19%)
 Grade 1101204 (13%)
 Grade 2000101 (3%)
 Grade 3010001 (3%)
Hypertension5 (16%)
 Grade 1001001 (3%)
 Grade 2001012 (7%)
 Grade 3001102 (7%)
Q2W
0.75 mg/kg 1 mg/kg 1.5 mg/kg 3 mg/kg Total
Adverse event a N = 6 N = 7 N = 3 N = 6 N = 22
Fatigue10 (46%)
 Grade 111226 (27%)
 Grade 211114 (18%)
Hypertension9 (41%)
 Grade 100000
 Grade 221227 (32%)
 Grade 320002 (9%)
Headache7 (32%)
 Grade 112126 (27%)
 Grade 210001 (5%)
Pulmonary hypertension3 (14%)
 Grade 100000
 Grade 201001 (5%)
 Grade 300112 (9%)
  • aGrades not listed have no events.